QCG
PLRX icon

Quadrant Capital Group’s Pliant Therapeutics PLRX Stock Holding History

Quadrant Capital Group’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-162
Closed -$2.81K – 2763
2023
Q3 		$2.81K Buy
+162
New +$2.81K ﹤0.01% 2306
2022
Q4 		– Sell
-51
Closed -$1K – 2823
2022
Q3 		$1K Buy
+51
New +$976 ﹤0.01% 2547

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Quadrant Capital Group's PLRX Position: Q4 2023 in Review

Quadrant Capital Group sold out of Pliant Therapeutics (PLRX) in Q4 2023, closing a stake of 162 shares — an estimated $2.81K sold.

Quadrant Capital Group first reported a position in PLRX in Q3 2022 and held it in 2 quarters. The position peaked at $2.81K in Q3 2023. 134 funds tracked by Wall St. Rank hold PLRX as of Q4 2023.

  • Quadrant Capital Group reported no remaining Pliant Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Quadrant Capital Group sold 162 Pliant Therapeutics shares in Q4 2023, an estimated $2.81K.
  • Quadrant Capital Group first reported a position in Pliant Therapeutics in Q3 2022 and held it in 2 quarters.
  • Quadrant Capital Group's Pliant Therapeutics position peaked at $2.81K in Q3 2023.
  • 134 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2023.

Based on Quadrant Capital Group's 13F filing for Q4 2023, filed 8 Feb 2024.